U.S. Markets closed

Hard To See If Regeneron's Eylea Combo Study Failure Reads Through To Ophthotech's Fovista

Jim Swanson

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced that the Phase 2 CAPELLA trial of Eylea co-formulated with an anti-PDGFR-beta antibody, runicumab, did not meet the primary endpoint.

Baird’s Brian P. Skorney maintained a Neutral rating on the company, with a price target of $448. He mentioned that the co-formulation arms performed worse than Eylea alone.

“While this is a high-profile failure for Regeneron, it implies higher risk of failure for potentially competitor, Fovista, but also makes Fovista's more dangerous to Eylea's market share, should it succeed,” the analyst stated.

Eylea monotherapy performed better than the co-formulation arms on both the primary and the secondary endpoints, including the anatomic endpoints of reduced retinal thickness and resolution of sub-retinal hyper-reflective material.

Related Link: Here's Why Ophthotech Is Trading Down On Regeneron's News

What It Means For Fovista

Ophthotech Corp’s (NASDAQ: OPHT) Fovista is currently in Phase 3 trials in combination with Avastin and Lucentis.

“If successful, we would expect to see a shift in market share away from Eylea towards Lucentis and Avastin due to the combination potential with Fovista,” Skorney said.

However, the failure of Regeneron’s own Eylea/anti-PDGFR combination might indicate that the Fovista results could also be negative.p

“Even if Fovista fails in Phase 3, we think it is important in the long-run that Regeneron has a next-generation co-formulation for Eylea to combat against biosimilar Lucentis erosion,” the analyst added.

Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!

Latest Ratings for REGN

Date Firm Action From To
Aug 2016 Baird Downgrades Outperform Neutral
Jun 2016 Bernstein Initiates Coverage on Outperform
Apr 2016 Wells Fargo Downgrades Outperform Market Perform

View More Analyst Ratings for REGN
View the Latest Analyst Ratings

See more from Benzinga

© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.